Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Michael Racke MD

Michael K. Racke MD

Professor of Neurology and Neuroscience; Director, Multiple Sclerosis Center, The Ohio State University Wexner Medical Center, Columbus, Ohio

Disclosures

Michael K. Racke has consulted for Biogen Idec, Diogenix, Novartis, Roche/Genetech, and Teva Neuroscience. He has received grant support from Diogenix, Biogen Idec, Novartis, and Roche/Genentech. 

Recent Contributions to PracticeUpdate:

  1. Long-Term Safety and Efficacy of Alemtuzumab for Multiple Sclerosis